Clinical features of Guillain–Barré syndrome with anti‐neurofascin 155 antibody
- 4 August 2022
- journal article
- research article
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 146 (5), 553-561
- https://doi.org/10.1111/ane.13678
Abstract
Objective Anti-neurofascin 155 (NF155) antibody has been discovered in chronic demyelinating conditions. However, the positive rate and clinical description were insufficient in acute demyelinating conditions, such as Guillain-Barre syndrome (GBS). This study aimed to explore the positive rate of anti-NF155 antibody in GBS patients and determine whether there were unique clinical characteristics in these patients. Materials & Methods Serum anti-NF155 antibody was detected from 94 GBS patients and 50 sex- and age-matched healthy controls using cell-based assay and tissue-based assay with immunostaining of mouse teased sciatic nerve fibers. Clinical characteristics, laboratory data, and electrophysiology examinations were retrospectively collected. Results Seven of 94 (7.45%) GBS patients were positive for anti-NF155 antibody, and the main IgG subclass was IgG1. Compared with anti-NF155 antibody-negative GBS patients, anti-NF155 antibody-positive GBS patients had a higher GBS disability score at nadirs (p = .010), higher modified Erasmus GBS outcome score (p = .022), higher rate of abnormal compound motor action potential (CMAP) amplitude (p = .002), higher frequency of prolonged F-wave latency (p < .001), lower frequency of abnormal sensory conduction velocity (p < .001) and sensory nerve action potential amplitude (p < .001), more axonal type (p = .040), and poorer therapeutic effect (p = .017). Conclusions Anti-NF155 antibody exists in a small portion of GBS patients. Anti-NF155 antibody-positive GBS patients possibly have a more severe clinical course, less sensory nerves involved, higher proportion of axonal type, poorer therapeutic effect, and worse prognosis, but the pathogenicity of the anti-NF155 antibody in GBS needs further study.Keywords
Funding Information
- National Natural Science Foundation of China (81771363)
This publication has 38 references indexed in Scilit:
- Anti-neurofascin antibody in combined central and peripheral demyelinationClinical and Experimental Neuroimmunology, 2013
- Nodo-paranodopathy: Beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathiesClinical Neurophysiology, 2013
- Neuro-glial interactions at the nodes of Ranvier: implication in health and diseasesFrontiers in Cellular Neuroscience, 2013
- Neurofascin as a target for autoantibodies in peripheral neuropathiesNeurology, 2012
- Electrodiagnostic criteria for Guillain–Barrè syndrome: A critical revision and the need for an updateClinical Neurophysiology, 2012
- Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-AnalysisNeuroepidemiology, 2011
- Early recognition of poor prognosis in Guillain-Barré syndromeNeurology, 2011
- Guillain–Barré syndrome and Fisher syndrome: Case definitions and guidelines for collection, analysis, and presentation of immunization safety dataVaccine, 2011
- Neurofascin as a novel target for autoantibody-mediated axonal injuryThe Journal of Experimental Medicine, 2007
- Neurofascins Are Required to Establish Axonal Domains for Saltatory ConductionNeuron, 2005